what this node claims
Initial digest — GLP-1R
AlphaFold v6 prediction landed for **GLP-1R** (Glucagon-like peptide-1 receptor). UniProt accession: `P43220`. Lane: `metabolic`. Mean per-residue pLDDT: **81.51**. Most commercially active peptide target of the decade.
vertical proof spine
evidence / risk instrument
39%
low debt pressure
29%
28%structuredebt
pLDDT pending
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, alphafold_metric, candidate, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence
- 0.6
- evidence refs
- 1
AlphaFold metrics visual
Confident backbone model
463 residues / min 27.03 / max 98.25 / source alphafold db
Very high
47.1%
218 residues / >=90
Confident
35.6%
165 residues / 70-89
Low
5.8%
27 residues / 50-69
Very low
11.4%
53 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 463 of 463 residues.
- residues 432-463 / mean 43.36
- residues 1-30 / mean 39.91
- residues 130-137 / mean 55.76
- residues 370-376 / mean 59.89
proof debt register
29%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.